Evaxion A/S (NASDAQ:EVAX – Get Free Report) and Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.
Volatility and Risk
Evaxion A/S has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.
Institutional and Insider Ownership
11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evaxion A/S | $7.53 million | 3.47 | -$7.71 million | ($1.21) | -2.59 |
| Nektar Therapeutics | $55.23 million | 43.12 | -$164.08 million | ($6.70) | -10.41 |
Evaxion A/S has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and price targets for Evaxion A/S and Nektar Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evaxion A/S | 1 | 0 | 5 | 0 | 2.67 |
| Nektar Therapeutics | 1 | 2 | 9 | 1 | 2.77 |
Evaxion A/S currently has a consensus price target of $11.00, indicating a potential upside of 251.44%. Nektar Therapeutics has a consensus price target of $141.50, indicating a potential upside of 102.84%. Given Evaxion A/S’s higher probable upside, analysts clearly believe Evaxion A/S is more favorable than Nektar Therapeutics.
Profitability
This table compares Evaxion A/S and Nektar Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evaxion A/S | N/A | -61.43% | -34.23% |
| Nektar Therapeutics | -287.84% | -37.87% | -25.67% |
Summary
Nektar Therapeutics beats Evaxion A/S on 9 of the 15 factors compared between the two stocks.
About Evaxion A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.
